Abstract Streptococcus pyogenes (Group A Streptococcus; GAS) is exquisitely adapted to
the human host, resulting in asymptomatic infection, pharyngitis, pyoderma, scarlet fever or …

Opinion statement Early recognition of group A streptococcal pharyngitis and appropriate
management with benzathine penicillin using local clinical prediction rules together with …

Abstract Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterial pathogen for
which a commercial vaccine for humans is not available. Employing the advantages of high …

Abstract Group A Streptococcus (GAS) infections result in a considerable underappreciated
burden of acute and chronic disease globally. A 2018 World Health Assembly resolution …

Streptococcus pyogenes is an important global pathogen, causing considerable morbidity
and mortality, especially in low and middle income countries where rheumatic heart disease …

The high strain diversity of Streptococcus pyogenes serves as a major obstacle to vaccine
development against this leading global pathogen. We did a systematic review of studies in …

Preclinical antigen discovery, vaccine formulation, and efficacy studies in animal models
have progressed significantly in recent years. There is now a need to move promising …

In recent years, whole-genome sequencing (WGS) has been perceived as a technology with
the potential to revolutionise clinical microbiology. Herein, we reviewed the literature on the …

While the incidence of many diseases has declined in developed countries, regions of the
world with low income and poor infrastructure continue to suffer a high burden of …

Streptococcus pyogenes (group A Streptococcus, GAS) is a human‐adapted pathogen
responsible for a wide spectrum of disease. GAS can cause relatively mild illnesses, such as …